Biotech Compounds
Cagri-GLP3R
Research Compound

Cagri-GLP3R

Cagri-GLPR3 is a dual-peptide blend combining cagrilintide, a long-acting acylated amylin analog and non-selective amylin/calcitonin (AMYR/CTR) receptor agonist, with GLP3R, a triple agonist targeting the GLP-1, GIP, and glucagon receptors. The pairing combines amylin-receptor and incretin/glucagon-receptor signaling pathways in a single formulation.

Select Size
10mg
SKU: RC10
Batch: 202607-01-RC10
$118.99
Ships within 7-14 business days
Volume Discounts
Qty: 1 - 4$118.99 each
Qty: 5 - 9$107.09 each(save $11.90)
Qty: 10+$95.19 each(save $23.80)
Quantity:
1
Out of Stock
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Categories:
HormonalInhibitoryTherapeutic
Tags:
cagrilintideamylin analogamylin receptor agonistcalcitonin receptorAMYRCTRtriple agonistGLP-1GLP-1 receptor agonistGIPGIPRglucagon receptorGCGRincretinmetabolicappetite regulationsatietyenergy balancegastric emptyingglucose regulationweight managementacylated peptidelong-acting peptidelyophilized powderpeptide blendcombination peptide

Product Details

Cagri-GLP3R combines two structurally distinct metabolic peptides engineered for extended half-life and albumin binding.


Cagrilintide is a 39-amino-acid acylated analog of amylin, the pancreatic hormone co-secreted with insulin. It acts as a non-selective agonist at amylin receptors (AMYR) and the calcitonin receptor (CTR), pathways associated with satiety signaling, gastric emptying rate, and energy balance. A C20 fatty-diacid modification and a C3–C8 disulfide bridge confer stability and a prolonged duration of action.


GLP-3R (GLP-3R) is a 39-amino-acid synthetic peptide built on a GIP backbone, incorporating non-coded residues (Aib2, Aib20, α-Me-Leu13) and a C20 fatty-diacid conjugation for albumin binding. It functions as a unimolecular triple agonist of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), reported binding affinities place it in the low-nanomolar range across all three targets.

The blend brings together amylin-receptor signaling and combined incretin/glucagon-receptor signaling, two mechanistically independent axes of metabolic and energy-balance regulation, within a single formulation. Both components are supplied as lyophilized powder.


Disclaimer: This product is intended strictly for laboratory and in-vitro applications. It is not a drug, food, or cosmetic and is not for human or veterinary consumption. Not for diagnostic or therapeutic use. Handling should be performed only by qualified personnel.

Frequently Asked Questions About Cagri-GLP3R

Answers summarize published research and are provided for laboratory research purposes only.

Cagri-GLP3R is a dual-peptide lyophilized research blend from Biotech Compounds. It combines Cagrilintide, a 39-amino acid long-acting acylated amylin analog that acts as a non-selective amylin and calcitonin receptor agonist, with GLP-3R, a 39-amino acid synthetic peptide that is a triple agonist of the GLP-1, GIP, and glucagon receptors. Both components carry a C20 fatty di-acid modification for albumin binding.
Research studies have shown that the two peptides in Cagri-GLP3R act through independent signaling axes. Researchers have reported that Cagrilintide activates amylin receptors and the calcitonin receptor, pathways associated with satiety and gastric emptying. GLP-3R has been observed in research to bind the glucagon, GIP, and GLP-1 receptors with low nanomolar affinity, combining incretin signaling with glucagon receptor driven energy expenditure.
The primary research area for Cagri-GLP3R is energy balance and body weight regulation. In animal models, researchers reported that triple agonist peptides in the GLP-3R class produced reductions in body weight and fat mass, and that adding an amylin receptor agonist to incretin signaling produced additive effects on food intake. Cagri-GLP3R packages both approaches for laboratories studying these metabolic pathways together.
Beyond body weight, the components of Cagri-GLP3R have been examined in glucose regulation and liver research. Published research suggests that triple receptor agonists in the GLP-3R class have been studied for effects on glycemic markers and liver fat in clinical trial participants. Cagrilintide has been examined in rodent studies for its influence on meal patterns and gastric emptying rate.
The two peptides in Cagri-GLP3R have been studied separately. GLP-3R, the triple agonist, has been evaluated in animal models and in phase 2 clinical trials with body weight and glycemic endpoints. Cagrilintide has been studied alone and in combination with a GLP-1 receptor agonist in clinical trials. The specific Cagri-GLP3R pairing is an investigational research combination and has not itself been approved as a medicine.
Both blends pair Cagrilintide with an incretin class peptide. Cagri-GLP3R uses GLP-3R, a triple agonist of the GLP-1, GIP, and glucagon receptors built on a GIP backbone. Cagri-GLP1S uses GLP-1S, a single-target GLP-1 receptor agonist. Researchers who want to study glucagon receptor activation alongside amylin signaling choose Cagri-GLP3R; those studying GLP-1 signaling alone with amylin choose Cagri-GLP1S.
Cagri-GLP3R is supplied as lyophilized powder that requires reconstitution before use. Bacteriostatic water is added slowly along the inner wall of the vial and the contents are swirled gently until fully dissolved. Cagri-GLP3R should never be shaken, since both peptides carry fatty di-acid chains and non-coded residues that agitation can disturb. Bacteriostatic Water is available on the site as a diluent.
Lyophilized Cagri-GLP3R should be stored at -20 C, protected from light and moisture. Once reconstituted, Cagri-GLP3R should be refrigerated at 2 to 8 C, protected from light, and not subjected to repeated freeze thaw cycles. Both peptides were engineered for extended half-life in research through albumin binding, but prepared solutions should still be handled with standard cold chain care.
Yes. Cagri-GLP3R from Biotech Compounds is supplied at 99 percent or greater purity and is third-party tested. A Certificate of Analysis is available on the Cagri-GLP3R product page so researchers can review identity and purity results for the blend before use. Each lot of Cagri-GLP3R is tested independently.
Research has reported that both peptides in Cagri-GLP3R were engineered for extended duration. Cagrilintide carries a C20 fatty di-acid modification and a Cys3-Cys8 disulfide bridge that confer stability and prolonged action. GLP-3R incorporates non-coded residues including Aib2, Aib20, and alpha-methyl-leucine at position 13, plus a C20 fatty di-acid conjugation for albumin binding. Researchers have observed that these features slow enzymatic breakdown and clearance.
No. Cagri-GLP3R from Biotech Compounds is sold strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 years of age or older. Cagri-GLP3R is not a drug or a dietary supplement, and it is not intended for human or animal consumption.
You May Also Like

Related Products

AOD-9604

AOD-9604

$43.99 / from
Aviptadil

Aviptadil

$215.99 / from
Cagri-GLP1S

Cagri-GLP1S

$64.99 / from
Cagrilintide

Cagrilintide

$86.99 / from